News & Updates
Filter by Specialty:

Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
byStephen Padilla
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.